文献速递抗栓抗凝管理药物不良反应与药物警戒

鱼精蛋白逆转肝素后使用阿替普酶治疗急性缺血性卒中:病例报告与综述

Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review.
PubMed 文献 · Pharmacotherapy · 2017-09-04

本文报告一例73岁男性急性缺血性卒中患者,在经皮冠状动脉介入治疗后突发左侧偏瘫和吞咽困难,NIHSS评分12分,aPTT超过150秒;在鱼精蛋白40 mg逆转肝素后,于最后已知良好时间144分钟时给予全剂量静脉阿替普酶0.9 mg/kg,25小时随访影像显示右侧脑桥和小脑梗死无出血,3个月改良Rankin量表评分为3分。作者主张对严重残疾且不适合机械取栓的患者谨慎评估逆转急性抗凝以促进阿替普酶给药。

要点

  • 鱼精蛋白逆转肝素后使用全剂量阿替普酶可能为部分急性缺血性卒中患者提供治疗机会
  • 本病例在阿替普酶后25小时影像未见出血,3个月mRS评分为3分
  • 该策略需谨慎评估,仅适用于不适合机械取栓的严重残疾患者

核心结论

  • 鱼精蛋白逆转肝素后使用全剂量静脉阿替普酶在本文报告的病例中未观察到不良事件,作者主张对此类患者进行谨慎评估以促进阿替普酶给药。

研究设计与样本

  • 病例报告与综述,报告一例73岁男性急性缺血性卒中患者在接受经皮冠状动脉介入治疗后发生卒中并接受鱼精蛋白逆转肝素后阿替普酶治疗。

主要发现

  • 患者经皮冠状动脉介入治疗后1小时突发左侧偏瘫和吞咽困难,NIHSS评分为12分,aPTT超过150秒。
  • 首次aPTT超过150秒,45分钟后复查aPTT为110秒,此时给予鱼精蛋白40 mg静脉注射。
  • 在最后已知良好时间144分钟时给予全剂量静脉阿替普酶0.9 mg/kg。
  • 25小时随访头部影像显示右侧脑桥和小脑急性缺血性卒中,无出血证据。
  • 患者2天后转至住院康复,3个月时改良Rankin量表评分为3分,出院时为5分。

临床怎么用

  • 对于接受急性抗凝治疗且不适合机械取栓的严重残疾急性缺血性卒中患者,可谨慎评估逆转抗凝后使用阿替普酶的可能性。

局限性

  • 本文为单例病例报告,结果不能推广至所有接受抗凝治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Few patients presenting with acute ischemic stroke (AIS) are eligible for alteplase, especially those receiving ongoing anticoagulation. We describe the first reported case of a patient receiving full-dose intravenous (IV) alteplase for AIS after heparin reversal with protamine. A 73-year-old man presented with AIS. He was treated with IV heparin, tirofiban, loading-dose prasugrel, and aspirin before percutaneous coronary intervention (PCI) for placement of a right coronary artery stent. One hour following PCI, he abruptly developed left hemiparesis and dysphagia. The National Institutes of Health Stroke Scale was 12, and activated partial thromboplastin time (aPTT) was longer than 150 seconds. Head computed tomography (CT) showed no acute pathology, and CT angiogram showed no large-vessel occlusion amenable to mechanical thrombectomy. Repeat aPTT, obtained 45 minutes later, was 110 seconds, at which time protamine 40 mg IV was administered. At 144 minutes from last known well time, full-dose IV alteplase (0.9 mg/kg) was administered. Follow-up head imaging at 25 hours showed right pontine and cerebellar AIS with no evidence of hemorrhage. The patient was discharged to inpatient rehabilitation 2 days later. Modified Rankin Scale at 3 months was 3, improved from 5 at discharge. Given the lack of adverse events associated with IV alteplase in our patient, we advocate cautious evaluation for potential reversal of acutely administered anticoagulation to facilitate alteplase administration in severely disabled patients who are not eligible for mechanical intervention and would have been excluded from definitive AIS treatment.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Fontaine GV, Smith SM. Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review. Pharmacotherapy. 2017. PMID: 28741720. doi:10.1002/phar.1997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。